Our cellular immunotherapy partnerships through NantWorks are developing novel science and medicines including CAR.TNK® technology.

 | read more »

Immunotherapy NANTiBody JV

NantCell LLC and Sorrento Therapeutics have established a joint venture to focus on the development of a Phase III mAb drug and multiple novel mAbs for valuable drug targets.


Sorrento and NantBioScience, Inc., a subsidiary of NantWorks, have established a joint venture, called NantCancerStemCell, LLC to focus on the development of “first-in-class” small molecules against targets which may address important drivers of cancer growth including cancer stem cells.

 | read more »

Lee’s Pharma

Lee’s Pharma has licensed exclusive rights from Sorrento to develop and commercialize the fully human anti-PD-L1 monoclonal antibody (mAb) STI-A1014 for the greater Chinese market, including Mainland China, Hong Kong, Macau, and Taiwan.

 | read more »

Morphotek / Eisai

Concortis Biosystems, Inc., a subsidiary of Sorrento Therapeutics, has entered into a collaboration agreement to generate novel antibody drug conjugates (ADCs) based on a Morphotek antibody linked to chemotherapeutic agents using Concortis’ proprietary ADC Technology.

 | read more »

MabTech Limited

Sorrento has entered into an exclusive licensing agreement to develop and commercialize multiple prespecified and undisclosed biosimilar or biobetter antibodies from Mabtech Limited, a holding company for premier antibody development and manufacturing companies in China.

 | read more »